All News

The published findings show the viability of using a transperineal ultrasound system as a means to monitor intra-fractional prostate motion for prostate stereotactic body radiotherapy.

The authors suggest that metastasis-free survival may serve as a more suitable end point for future clinical trials of radiation therapy in localized prostate cancer.

The UK REIMAGINE study suggests that MRI screening can not only bolster PSA screening, but also has the potential to be the central component of a national prostate cancer screening program.

Prostate cancer survivor Larry Ferguson, DMD, participated in a clinical trial at MUSC Hollings Cancer Center.

The BioProtect Balloon Implant System provides protection to the rectum during radiation therapy for prostate cancer.

"I'm very pleased that this is now in the armamentarium for us," says Wayne G. Brisbane, MD.

The signatures were derived from the Decipher Genomics Resource for Intelligent Discovery (GRID) database in a retrospective analysis of the phase 2 STREAM study.

The application is specifically for use of enzalutamide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence and is supported by data from the phase 3 EMBARK trial.

In predicting PCSM at 10 years, the area under the curve with the P-score was 0.93, compared with 0.81 with D’Amico and 0.88 with CAPRA.

Patients in the CONTACT-02 trial were randomly assigned 1:1 to receive cabozantinib plus atezolizumab or a second novel hormonal therapy of either abiraterone and prednisone or enzalutamide.

The study assessed MG-AGEs, SRAGE, GLO1, and AGER, 4 biomarkers that are associated with methyglyoxal.

"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.

The urine-based assay measures the expression of HOXC6 and DLX1 to determine whether a patient may benefit from prostate biopsy.

The novel test was developed and validated using the biomarkers Appl1, Sortilin, and Syndecan-1 that were studied by investigators at the University of South Australia.

The studies explored the use of opioids following surgery as well as the risk of incisional hernia.

"The study revealed that the anatomical changes in the male pelvis could potentially favor the upright position for prostate treatments,” says Niek Schreuder.

The PRESERVE study of the NanoKnife System for the ablation of prostate tissue is exploring the focal treatment in patients with intermediate-risk prostate cancer.

Patients classified as high-risk by the genomic classifier who underwent radical prostatectomy had a 3-fold higher risk of harboring adverse pathology at the time of surgery compared with those with low-risk.

"Patients and providers should be aware of the long-term risks of radiation exposure when weighing treatment decisions,” says Avi Baskin, MD, MPhil.

Yale Urology Chair Isaac Y. Kim, MD, PhD, MBA, has published his concerns surrounding interpreted results in the landmark ProtecT Study.

The Vanquish device is currently being assessed in the VAPOR 2 trial, which is evaluating the treatment in patients with intermediate risk, localized prostate cancer.

“Increasing the representation of physicians (or actors) who appear concordant with the target audience may be an important tool for more effective health communication strategies to mitigate health disparities," the authors write.

“Water vapor therapy shows great promise to provide patients with another option to proactively manage their cancer risk while preserving quality of life,” said Naveen Kella, MD.

ARX517 is currently being studied in the phase 1/2 open-label APEX-01 trial.

"The beauty is, now we can deliver a cisplatin-based chemotherapeutic orally, which is usually never done. And by targeting the prostate, we can reduce kidney and liver toxicity and the risk of peripheral neuropathy," says Shanta Dhar, PhD.

The prospective cohort study seeks to enroll 200 patients from the South Florida region and 1800 patients from international sites.

"Our most significant finding may be that patients experience financial toxicity despite their ability to remain compliant with treatment," says Daniel D. Joyce, MD.

“To our knowledge, these results are the first to suggest an association between second-generation [antiandrogens] and cognitive and functional toxic effects based on data from prospective [randomized controlled trials],” the investigators wrote.

The new space includes a clinical laboratory for IsoPSA testing, labs for research and development, offices, and manufacturing spaces for production and distribution of in vitro diagnostic kits.

"About 29% of our high-risk patients tested AI biomarker negative, and they could thus be spared the long-term [adverse] effects of ADT for 2 to 3 years," says Andrew J. Armstrong, MD, MSc.